Recently, a number of leading companies, such as E-Fangda Fund, Huaxia Fund, Fuguo Fund, and Huitianfu Fund, have intensively listed innovative Hong Kong stocks. After 4 individual stocks, including Baiaosetu-B, Sansheng Pharmaceutical, Shiyao Group, and Colunbotai Biotech, were increased, their shareholding ratio hit or exceeded the legal listing line of 5%. Meanwhile, the Hang Seng Innovative Drugs Index has rebounded more than 20% since the end of June. Industry insiders believe that under the multiple resonances of the release of policy dividends, large-scale implementation of domestic innovative drug BD, the emergence of profit inflection points for leading pharmaceutical companies, and sector valuations, the Hong Kong stock innovative drug sector may usher in an allocation window.

Recently, a number of leading companies, such as E-Fangda Fund, Huaxia Fund, Fuguo Fund, and Huitianfu Fund, have intensively listed innovative Hong Kong stocks. After 4 individual stocks, including Baiaosetu-B, Sansheng Pharmaceutical, Shiyao Group, and Colunbotai Biotech, were increased, their shareholding ratio hit or exceeded the legal listing line of 5%. Meanwhile, the Hang Seng Innovative Drugs Index has rebounded more than 20% since the end of June. Industry insiders believe that under the multiple resonances of the release of policy dividends, large-scale implementation of domestic innovative drug BD, the emergence of profit inflection points for leading pharmaceutical companies, and sector valuations, the Hong Kong stock innovative drug sector may usher in an allocation window.